Release date- 22082019 -
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc.
- UK-based specialist HIV company
ViiV Healthcare, which is majority owned by UK-based pharmaceutical company GlaxoSmithKline plc (LSE: GSK), with Pfizer Inc.
ViiV's Long-Acting HIV Drug Combo Aces Late-Stage Trial
(Alliance News) - GlaxoSmithKline PLC on Thursday said
ViiV Healthcare reported positive headline results from its global phase III ATLAS-2M study.
ViiV Healthcare, a company majority owned by GSK (GS), with Pfizer (PFE), and Shionogi Limited as shareholders, announced positive headline results from its global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen, or 2DR, of
ViiV Healthcare's cabotegravir and Janssen's rilpivirine for the treatment of HIV.
ViiV Healthcare, a specialist HIV company majority owned by GSK, along with Pfizer Inc and Shionogi Limited as shareholders has revealed data from its phase III TANGO study for treatment of HIV, it was reported yesterday.
Max Lataillade is Head of Clinical Development for HIV,
ViiV Healthcare where He is responsible for the development of new medicines that address key unmet medical needs for HIV patients.
Boyd reported receiving personal fees from Janssen-Cilag and
ViiV Healthcare, while Dr.
LONDON --
ViiV Healthcare has been granted Food and Drug Administration approval for Juluca, a combination therapy indicated as a complete regimen for treating HIV-1 infection.
Fitch projects EBITDA margins will stabilise at just below 30%, as restructuring and product launches are executed and the vaccines and
ViiV businesses drive growth.